Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05062421 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Name: Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis. — clinical trial record (NCT05062421)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Arthritis

StatusRecruiting

PhaseNot specified

SponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Started2021-04-01

View on ClinicalTrials.gov ↗

Amendment history

2021-11-15

Study Status, Contacts/Locations v1

Re-verified, no change to tracked fields

2021-09-20

Original filing

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

27 trials monitored

See all monitored trials

Rheumatoid Arthritis

612 trials monitored

See 11 trials at risk

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Trial Details

NCT Number	NCT05062421
Lead Sponsor	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions	Arthritis, Rheumatoid
Enrollment	540 participants
Start Date	2021-04-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2021-11-17